• Axsome Therapeutics recently presented new AUVELITY® (dextromethorphan-bupropion) data in major depressive disorder at the 2026 American Society of Clinical Psychopharmacology Annual Meeting in Miami, including analyses on anxious distress and real-world switching outcomes.
• The fresh AUVELITY® findings, particularly around anxious symptoms and real-world effectiveness, could meaningfully refine how clinicians and payers view the drug’s role in treating major depressive disorder.
• We’ll now explore how these new AUVELITY® data on anxious distress and real-world outcomes might influence Axsome’s broader investment narrative.

The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Axsome Therapeutics Investment Narrative Recap

To own Axsome, you need to believe that AUVELITY and a small CNS portfolio can eventually support a profitable, durable business, despite current losses and high spending. The new AUVELITY data in anxious distress and real-world switching looks directionally helpful for reinforcing the MDD story, but it does not obviously change the near term focus on executing recent launches or the key risk of payer pressure and concentrated product dependence.

The most relevant recent announcement alongside this new MDD data is AUVELITY’s April 2026 FDA approval for agitation in dementia due to Alzheimer’s disease. That label expansion broadens AUVELITY’s potential reach beyond depression, while the new psychopharmacology data speaks to how the same product might perform within its original MDD indication. Together, they frame both the opportunity and the execution risk tied to Axsome’s reliance on a few core commercial assets.

Yet against that upside, investors should also be aware of the risk that rising gross to net discounts and payer pushback could...

Axsome Therapeutics' narrative projects $2.5 billion revenue and $932.4 million earnings by 2029.

Uncover how Axsome Therapeutics' forecasts yield a $266.94 fair value, a 13% upside to its current price.

Exploring Other Perspectives

Some of the lowest analysts were already cautious, assuming about US$1.5 billion revenue and US$433.1 million earnings by 2029, so fresh AUVELITY data could either soften or reinforce that more pessimistic view of Axsome’s heavy AUVELITY reliance.

Explore 8 other fair value estimates on Axsome Therapeutics - why the stock might be worth over 3x more than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Axsome Therapeutics research is our analysis highlighting 2 key rewards that could impact your investment decision.
• Our free Axsome Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Axsome Therapeutics' overall financial health at a glance.

Interested In Other Possibilities?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• This technology could replace computers: discover 28 stocks that are working to make quantum computing a reality.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 14 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.